Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has recently seen a shift in consensus forecasts following its latest report. The outlook for the company has become slightly more pessimistic according to analysts. This news may have an impact on investors and shareholders of Marinus Pharmaceuticals.